Evidence map›Paper›PMID 39050879›Full record

ArticleInternational journal of nanomedicine2024

Layer-by-Layer Nanoparticles for Calcium Overload in situ Enhanced Reactive Oxygen Oncotherapy.

Boye Zhang, Jianliang Man, Lingyun Guo, Xiaoxia Ru, Chengwu Zhang, Wen Liu, Lihong Li, Sufang Ma, Lixia Guo, Haojiang Wang and 4 more

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Boye ZhangSchool of Basic Medical Sciences, Shanxi Medical University, Taiyuan, 030001, People's Republic of China.
Jianliang ManAcademy of Medical Sciences, Shanxi Medical University, Taiyuan, 030001, People's Republic of China.
Lingyun GuoSchool of Basic Medical Sciences, Shanxi Medical University, Taiyuan, 030001, People's Republic of China.
Xiaoxia RuSchool of Basic Medical Sciences, Shanxi Medical University, Taiyuan, 030001, People's Republic of China.
Chengwu ZhangSchool of Basic Medical Sciences, Shanxi Medical University, Taiyuan, 030001, People's Republic of China.
Wen LiuSchool of Basic Medical Sciences, Shanxi Medical University, Taiyuan, 030001, People's Republic of China.
Lihong LiSchool of Basic Medical Sciences, Shanxi Medical University, Taiyuan, 030001, People's Republic of China.
Sufang MaSchool of Basic Medical Sciences, Shanxi Medical University, Taiyuan, 030001, People's Republic of China.
Lixia GuoShanxi Province Brain Degenerative Diseases Precision Diagnosis and Treatment Engineering Research Center, Shanxi Medical University, Jinzhong, 030606, People's Republic of China.
Haojiang WangSchool of Basic Medical Sciences, Shanxi Medical University, Taiyuan, 030001, People's Republic of China.
Bin WangSchool of Basic Medical Sciences, Shanxi Medical University, Taiyuan, 030001, People's Republic of China.
Haipeng DiaoSchool of Basic Medical Sciences, Shanxi Medical University, Taiyuan, 030001, People's Republic of China.
Renchao CheLaboratory of Advanced Materials, Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials, Academy for Engineering &Technology, Fudan University, Shanghai, 200438, People's Republic of China.
Lili YanSchool of Basic Medical Sciences, Shanxi Medical University, Taiyuan, 030001, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Challenges such as poor drug selectivity, non-target reactivity, and the development of drug resistance continue to pose significant obstacles in the clinical application of cancer therapeutic drugs. To overcome the limitations of drug resistance in chemotherapy, a viable treatment strategy involves designing multifunctional nano-platforms that exploit the unique physicochemical properties of tumor microenvironment (TME). Methods: Herein, layer-by-layer nanoparticles with polyporous CuS as delivery vehicles, loaded with a sonosensitizer (tetra-(4-aminophenyl) porphyrin, TAPP) and sequentially functionalized with pH-responsive CaCO Results: CuS@TAPP-CaCO Conclusion: Collectively, the development of CTCH presents a novel therapeutic strategy for tumor treatment by effectively responding to the acidic TME, thus holding significant clinical implications.

Indexed as

CalciumCalcium CarbonateNanoparticlesTumor MicroenvironmentAnimalsAntineoplastic AgentsHeLa CellsHumansHyaluronic AcidHydrogen-Ion ConcentrationLayer-by-Layer NanoparticlesMiceMice, Inbred BALB CMice, NudeMitochondriaNeoplasmsAntineoplastic AgentsCalciumCalcium CarbonateHyaluronic AcidPorphyrinsReactive Oxygen Speciescalcium overloadmitochondria damagepH-responsivereactive oxygen oncotherapysynergistic treatment

Identifiers

PMID39050879
PMCPMC11268784

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.